As of 2025-12-25, the Relative Valuation of BridgeBio Pharma Inc (BBIO) is (76.73) USD. This relative valuation is based on P/E multiples. With the latest stock price at 76.53 USD, the upside of BridgeBio Pharma Inc based on Relative Valuation is -200.3%.
The range of the Relative Valuation is (75.94) - (75.86) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.0x - 18.3x | 18.1x |
| Forward P/E multiples | 18.4x - 21.4x | 19.0x |
| Fair Price | (75.94) - (75.86) | (76.73) |
| Upside | -199.2% - -199.1% | -200.3% |
| Date | P/E |
| 2025-12-23 | -18.47 |
| 2025-12-22 | -18.64 |
| 2025-12-19 | -18.45 |
| 2025-12-18 | -17.92 |
| 2025-12-17 | -17.89 |
| 2025-12-16 | -18.30 |
| 2025-12-15 | -18.01 |
| 2025-12-12 | -18.17 |
| 2025-12-11 | -17.91 |
| 2025-12-10 | -17.58 |
| 2025-12-09 | -17.33 |
| 2025-12-08 | -17.95 |
| 2025-12-05 | -17.80 |
| 2025-12-04 | -18.07 |
| 2025-12-03 | -17.93 |
| 2025-12-02 | -17.28 |
| 2025-12-01 | -17.35 |
| 2025-11-28 | -17.41 |
| 2025-11-26 | -17.34 |
| 2025-11-25 | -17.08 |
| 2025-11-24 | -17.16 |
| 2025-11-21 | -16.47 |
| 2025-11-20 | -15.62 |
| 2025-11-19 | -15.84 |
| 2025-11-18 | -15.86 |
| 2025-11-17 | -16.17 |
| 2025-11-14 | -16.05 |
| 2025-11-13 | -15.73 |
| 2025-11-12 | -16.01 |
| 2025-11-11 | -16.10 |
| 2025-11-10 | -15.18 |
| 2025-11-07 | -14.94 |
| 2025-11-06 | -15.17 |
| 2025-11-05 | -15.15 |
| 2025-11-04 | -14.84 |
| 2025-11-03 | -14.98 |
| 2025-10-31 | -15.14 |
| 2025-10-30 | -15.32 |
| 2025-10-29 | -16.11 |
| 2025-10-28 | -15.59 |
| 2025-10-27 | -15.37 |
| 2025-10-24 | -13.12 |
| 2025-10-23 | -13.01 |
| 2025-10-22 | -12.87 |
| 2025-10-21 | -13.14 |
| 2025-10-20 | -13.60 |
| 2025-10-17 | -13.28 |
| 2025-10-16 | -13.30 |
| 2025-10-15 | -13.69 |
| 2025-10-14 | -13.66 |